RTS,S/AS01
African children
IgA
IgG
Malaria.
Plasmodium falciparum
RTS, S vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
22 01 2021
22 01 2021
Historique:
received:
18
05
2020
revised:
05
11
2020
accepted:
10
12
2020
pubmed:
29
12
2020
medline:
28
4
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
The evaluation of immune responses to RTS,S/AS01 has traditionally focused on immunoglobulin (Ig) G antibodies that are only moderately associated with protection. The role of other antibody isotypes that could also contribute to vaccine efficacy remains unclear. Here we investigated whether RTS,S/AS01 Ninety-five children (age 5-17 months old at first vaccination) from the RTS,S/AS01 RTS,S vaccination induced a 1.2 to 2-fold increase in levels of serum/plasma IgA antibodies to all CSP constructs, which was not observed upon immunization with a comparator vaccine. The IgA response against 13 out of 16 vaccine-unrelated P. falciparum antigens also increased after vaccination, and levels were higher in recipients of RTS,S than in comparators. IgA levels to malaria antigens before vaccination were more elevated in the high MTI than the low MTI site. No statistically significant association of IgA with protection was found in exploratory analyses. RTS,S/AS01 ClinicalTrials.gov: NCT008666191.
Sections du résumé
BACKGROUND
The evaluation of immune responses to RTS,S/AS01 has traditionally focused on immunoglobulin (Ig) G antibodies that are only moderately associated with protection. The role of other antibody isotypes that could also contribute to vaccine efficacy remains unclear. Here we investigated whether RTS,S/AS01
METHODS
Ninety-five children (age 5-17 months old at first vaccination) from the RTS,S/AS01
RESULTS
RTS,S vaccination induced a 1.2 to 2-fold increase in levels of serum/plasma IgA antibodies to all CSP constructs, which was not observed upon immunization with a comparator vaccine. The IgA response against 13 out of 16 vaccine-unrelated P. falciparum antigens also increased after vaccination, and levels were higher in recipients of RTS,S than in comparators. IgA levels to malaria antigens before vaccination were more elevated in the high MTI than the low MTI site. No statistically significant association of IgA with protection was found in exploratory analyses.
CONCLUSIONS
RTS,S/AS01
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov: NCT008666191.
Identifiants
pubmed: 33358704
pii: S0264-410X(20)31606-6
doi: 10.1016/j.vaccine.2020.12.038
pii:
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Immunoglobulin A
0
Malaria Vaccines
0
Protozoan Proteins
0
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-698Subventions
Organisme : NIAID NIH HHS
ID : R01 AI095789
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.